Why Is Alcohol Use Declining in Canada?

Why It Matters

Reduced alcohol consumption promises significant public‑health gains and lower health‑care costs, while pressuring traditional alcohol producers to adapt to a changing market landscape.

Key Takeaways

• Per‑capita alcohol sales fell 18% to 6.8 L ethanol (399 drinks) in 2024‑25.
• Health warnings link alcohol to seven cancers, fueling sober‑curious trends.
• Higher inflation makes alcohol a price‑responsive good, cutting demand.
• Youth drinking rates have declined, lowering future adult consumption.
• GLP‑1 weight‑loss drugs reduce appetite for alcohol among middle‑aged adults.

Pulse Analysis

The latest Statistics Canada figures confirm a sustained contraction in alcohol consumption, with per‑capita sales now at their lowest level in two decades. While the pandemic briefly inflated drinking levels, the post‑COVID period has seen a sharper-than‑expected reversal, outpacing even pre‑pandemic baselines. This decline is not isolated to Canada; U.S. data show parallel drops, indicating a continent‑wide shift in drinking habits that analysts attribute to evolving social norms and heightened health consciousness.

Health considerations dominate the narrative. Recent research debunks the myth of moderate drinking benefits and links alcohol to seven major cancers, prompting movements like "sober‑curious" and campaigns such as Dry January. Simultaneously, inflation has eroded disposable income, making alcohol—a price‑elastic commodity—less affordable for many households. Demographic factors, including a surge in immigrants from lower‑drinking cultures and a steady decline in youth alcohol use, further depress overall demand. The rapid expansion of no‑ and low‑alcohol beverages offers an alternative, though its net effect on total alcohol volume remains uncertain.

The public‑health implications are profound. Lower consumption translates into fewer alcohol‑related hospitalizations, reduced mortality, and substantial savings for taxpayers, as alcohol‑related costs historically exceed tax revenues. For the industry, the challenge is to innovate—whether through premiumization, diversification into non‑alcoholic lines, or embracing minimum‑pricing policies that could paradoxically boost revenues while improving health outcomes. Whether this downward trajectory endures or rebounds will hinge on future policy choices, cultural attitudes, and emerging health‑tech interventions like GLP‑1 medications.